Welcome to our dedicated page for Bausch & Lomb SEC filings (Ticker: BLCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Bausch & Lomb's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Bausch & Lomb's regulatory disclosures and financial reporting.
Bausch + Lomb Corporation refreshed its board at the request of controlling shareholder Bausch Health Companies, appointing Thomas J. Appio, Robert Chersi, Laurence Paul, M.D., and Barbara Trebbi on August 5, 2026, to replace four resigning directors whose departures were not due to disagreements.
The company agreed to prorated cash compensation and accelerated full vesting of outstanding and unvested restricted stock units from the 2026 annual grants for the departing directors, and entered into a one-year consulting agreement with former director Thomas W. Ross, Sr. that pays $400,000 in four quarterly installments, terminable on notice or for cause.
For the quarter ended June 30, 2026, revenue was $1.394 billion, up 9% year over year on a reported basis and 8% in constant currency. Net cash provided by operating activities increased from $32 million in the first quarter to $153 million, and adjusted cash flow from operations rose from $45 million to $161 million. The company reaffirmed 2026 guidance for revenue of $5.440–$5.540 billion and Adjusted EBITDA excluding Acquired IPR&D of $1.025–$1.075 billion.
Bausch + Lomb, a global eye health company, reported Q2 2026 revenue of $1,394 million, up from $1,278 million a year earlier, largely from product sales of $1,389 million. Operating results improved to income of $83 million versus a loss of $11 million, and net loss attributable to the company narrowed to $14 million (loss per share $0.04) from $62 million (loss per share $0.18).
For the first half of 2026, revenue increased to $2,638 million from $2,415 million, while operating income was $116 million compared with a loss of $94 million. Net loss attributable to Bausch + Lomb was $85 million, improved from $274 million. Operating cash flow rose to $185 million from $10 million, after $171 million of capital expenditures and $53 million of acquisitions and other investments.
As of June 30, 2026, the company held $367 million of cash and cash equivalents and total assets of $13,859 million. Principal long-term debt was $5,128 million, including a $2,795 million term loan due 2031 and $1,400 million notes due 2028, with a weighted average stated interest rate of 7.43%. Bausch Health Companies Inc. owned approximately 87% of Bausch + Lomb’s common shares and continues to evaluate a potential separation and related transactions.
Bausch + Lomb Corporation reported second‑quarter 2026 revenue of $1.394 billion, up 9% year over year, or 8% on a constant‑currency basis, with growth across Vision Care, Surgical and Pharmaceuticals. Operating income was $83 million versus an $11 million loss, while GAAP net loss narrowed to $14 million. Adjusted net income was $55 million and Adjusted EBITDA reached $241 million; GAAP EPS improved to ($0.04) and Adjusted EPS rose to $0.15. Cash flow from operations increased to $153 million.
The company raised full‑year 2026 guidance, targeting revenue of $5.440–$5.540 billion and Adjusted EBITDA excluding Acquired IPR&D of $1.025–$1.075 billion, reflecting continued strong performance, partly offset by slightly lower expected foreign‑exchange tailwinds. A pivotal study of the enVista Beyond investigational IOL met several co‑primary endpoints and showed a favorable safety profile, though it narrowly missed certain predefined performance targets.
Bausch & Lomb Corp executive Luc Bonnefoy reported a routine tax-withholding transaction related to equity compensation. On the vesting of restricted share units, 1,008 common shares were withheld at an indicated value of $15.08 per share to satisfy tax obligations. After this non-market disposition, Bonnefoy directly holds 87,023 common shares.
VON ESCHENBACH ANDREW C. reported acquisition or exercise transactions in this Form 4 filing.
Bausch & Lomb Corp director Andrew C. Von Eschenbach received an annual equity grant of 15,842 common shares, reported as a grant or award at $15.78 per share. The award reflects restricted share units granted under the company’s 2022 Omnibus Incentive Plan and is scheduled to vest before the next annual shareholder meeting, bringing his direct holdings to 86,656 common shares.
Bausch & Lomb Corporation director Ross Thomas W. Sr. reported an acquisition of 15,842 common shares tied to a new equity award. The filing shows this as a grant of restricted share units (RSUs) under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated.
The RSUs are scheduled to vest on the date immediately preceding the conclusion of the next annual meeting of shareholders and will be settled in common shares. After this grant, Ross directly holds 85,233 common shares, indicating this is a routine annual equity award for a non-employee director rather than an open-market purchase.
ROBERTSON RUSSEL C reported acquisition or exercise transactions in this Form 4 filing.
Bausch & Lomb Corp director Russel C. Robertson received an equity award rather than buying shares on the market. He was granted 15,842 common shares at $15.78 per share as part of his annual restricted share unit (RSU) grant for non-employee directors.
Following this grant, he directly holds 94,260 common shares. The RSUs are scheduled to vest immediately before the company’s next annual meeting of shareholders and will then be settled in common shares under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan.
Bausch & Lomb Corp director John Paulson reported receiving a stock-based compensation award rather than making an open-market trade. He acquired 15,842 common shares at an accounting value of $15.78 per share through a grant of restricted share units under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan.
Following this award, his direct holdings rose to 89,823 common shares. The RSUs are scheduled to vest on the date immediately preceding the conclusion of the next annual meeting of shareholders and will be settled in common shares when vested.
Ling Karen reported acquisition or exercise transactions in this Form 4 filing.
Bausch & Lomb Corp director Karen Ling received an equity grant rather than buying shares on the market. She was awarded 15,842 common shares at a reference price of $15.78 per share as part of her annual restricted share unit (RSU) grant for non-employee directors. Following this award, she directly holds 61,518 common shares. The RSUs are scheduled to vest immediately before the conclusion of the next annual meeting of shareholders, when they will be settled in common shares.